It is hoped that reactivating the tumour-suppressor protein p53 will help to combat cancer. However, fresh evidence suggests it is unlikely that all cells in a tumour will respond to such treatment. See Letters p.567 & p.572
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer
Cell Death & Disease Open Access 07 February 2018
-
Runx3 plays a critical role in restriction-point and defense against cellular transformation
Oncogene Open Access 28 August 2017
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Feldser, D. M. et al. Nature 468, 572–575 (2010).
Junttila, M. R. et al. Nature 468, 567–571 (2010).
Martins, C. P., Brown-Swigart, L. & Evan, G. I. Cell 127, 1323–1334 (2006).
Ventura, A. et al. Nature 445, 661–665 (2007).
Xue, W. et al. Nature 445, 656–660 (2007).
Christophorou, M. A., Ringshausen, I., Finch, A. J., Brown Swigart, L. & Evan, G. I. Nature 443, 214–217 (2006).
Moore, L. et al. Oncogene 22, 7831–7837 (2003).
Sherr, C. J. Nature Rev. Cancer 6, 663–673 (2006).
Meek, D. W. Nature Rev. Cancer 9, 714–723 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berns, A. The blind spot of p53. Nature 468, 519–520 (2010). https://doi.org/10.1038/468519a
Published:
Issue Date:
DOI: https://doi.org/10.1038/468519a
This article is cited by
-
Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer
Cell Death & Disease (2018)
-
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Nature Neuroscience (2017)
-
Runx3 plays a critical role in restriction-point and defense against cellular transformation
Oncogene (2017)
-
RNAi: a potential new class of therapeutic for human genetic disease
Human Genetics (2011)
